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Behavioral/Cognitive
Optogenetic Stimulation of Prefrontal Glutamatergic
Neurons Enhances Recognition Memory
Abigail Benn, Gareth R. I. Barker, Sarah A. Stuart, XEva v. L. Roloff, XAnja G. Teschemacher, E. CleaWarburton,
and Emma S. J. Robinson
School of Physiology, Pharmacology, and Neuroscience, Faculty of Biomedical Sciences, University of Bristol, Bristol BS8 1TD, United Kingdom
Finding effective cognitive enhancers is amajor health challenge; however, modulating glutamatergic neurotransmission has the poten-
tial to enhance performance in recognitionmemory tasks. Previous studies using glutamate receptor antagonists have revealed that the
medial prefrontal cortex (mPFC) plays a central role in associative recognition memory. The present study investigates short-term
recognition memory using optogenetics to target glutamatergic neurons within the rodent mPFC specifically. Selective stimulation of
glutamatergic neurons during the onlinemaintenance of information enhanced associative recognitionmemory in normal animals. This
cognitive enhancing effectwas replicatedby local infusions of theAMPAkineCX516, but notCX546,whichdiffer in their effects onEPSPs.
This suggests that enhancing the amplitude, but not the duration, of excitatory synaptic currents improves memory performance.
Increasing glutamate release through infusions of the mGluR7 presynaptic receptor antagonist MMPIP had no effect on performance.
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Introduction
Glutamatergic neurons are the major projection neurons in the
cerebral cortex and are hypothesized to play a central role in
optimal cognitive function. Studies in animals have shown that
systemic or local administration of glutamate receptor antago-
nists produce impairments in a range of cognitive tasks, includ-
ing memory, attention, and impulse control (for review, see
Robbins andMurphy, 2006). In rodents, bothAMPAandNMDA
receptor antagonists impair recognition memory (Barker and
Warburton, 2008), as assessed by spontaneous object recognition
tasks (Ennaceur andDelacour, 1988). Such tasks are based on the
animals’ ability tomake judgments about the prior occurrence of
objects based on their relative familiarity and/or associations be-
tween objects and spatial locations. Previous studies have shown
that novel object preference (NOP), which requires the discrim-
ination between a novel and familiar object, is dependent on the
perirhinal cortex, whereas discriminations involving a familiar
object encountered in a new location (novel object location,
NOL) require the hippocampus (Hannesson et al., 2004;Winters
et al., 2004; Barker andWarburton, 2011). Object-in-place (OIP)
associative recognition memory, in which information concern-
ing the prior occurrence of multiple objects within specific
locations is used, requires both the perirhinal cortex and hip-
pocampus and also the medial prefrontal cortex (mPFC). It has
beenhypothesized that themPFCplays a role in the integration of
object familiarity and location information (Barker et al., 2007).
Therefore, our understanding of recognition memory stems
from such studies investigating impairments caused by drugs and
lesions (Hannesson et al., 2004;Winters et al., 2004; Barker et al.,
2007), yet these approaches lack cell-type specificity and can af-
fect the function of both glutamatergic and GABAergic neurons.
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Significance Statement
These results provide new mechanistic information that could guide the targeting of future cognitive enhancers. Our work
suggests that improved associative-recognition memory can be achieved by enhancing endogenous glutamatergic neuronal ac-
tivity selectively using an optogenetic approach. We build on these observations to recapitulate this effect using drug treatments
that enhance the amplitudeofEPSPs; however, drugs that alter thedurationof theEPSPor increase glutamate release lack efficacy.
This suggests that both neural and temporal specificity are needed to achieve cognitive enhancement.
4930 • The Journal of Neuroscience, May 4, 2016 • 36(18):4930–4939
The specific nature of how activity of mPFC glutamatergic neu-
rons relates to recognition memory performance remains to be
elucidated.
In this study, a light-activated cation channel, channel rho-
dopsin 2 (ChR2), driven by the cell-type-specific promoter
CaMKIIa was expressed in mPFC glutamate neurons using viral-
mediated gene transfer (Aravanis et al., 2007; Ji and Neugebauer,
2012). We hypothesized that facilitation of glutamatergic neu-
rotransmission via optogenetic activation of mPFC pyramidal
neurons would improve associative recognition memory in
normal animals, opposite to the effects seen when glutamate re-
ceptors are antagonized (Barker and Warburton, 2008). Initial
studies confirmed the specificity and in vivo expression of the
ChR2 construct expressed using a lentiviral vector. To assess as-
sociative recognition memory in rats, the OIP was used. Because
neither NOP nor NOL is dependent on the mPFC, both tasks
provided additional specificity control (Winters et al., 2004;
Barker and Warburton, 2011). It has been demonstrated previ-
ously that changes in firing characteristics occur during short-
term memory tasks in which subpopulations of PFC neurons
exhibit enhanced activity during the delay phase (Jung et al.,
1998; Goldman-Rakic et al., 2000; Chang et al., 2002). Therefore,
light stimulation was delivered to the mPFC during the 5 min
delay phase of each task. After the behavior studies, cFos expres-
sion in the mPFC and connecting regions, including the perirhi-
nal cortex and hippocampus, were quantified and the extent of
neuronal activation associated with the ChR2 expression was
measured.
The effects of optogenetic stimulation of glutamatergic neu-
rons may be recapitulated by pharmacological enhancement
of endogenous activity using positive allosteric modulation of
AMPA receptors. We tested this hypothesis by examining OIP
performance aftermPFC infusions of theAMPAkinesCX516 and
CX546 during the delay phase. These compounds have been re-
ported to improve memory performance (Damgaard et al.,
2010). They preferentially enhance glutamatergic output, but dif-
fer in their effects on EPSCs (Arai et al., 2002; Xia andArai, 2005),
enabling us to investigate possible mechanisms underlying the
optogenetic effects observed.We also tested anmGluR7 receptor
antagonist, MMPIP, which enhances glutamatergic neurotrans-
mission by blocking presynaptic autoreceptors (Suzuki et al.,
2007).
Materials andMethods
Subjects. Subjects were male, Lister hooded rats weighing 300–350 g
(Harlan) at the start of each experiment (n  29, total for the whole
study). Separate cohorts of animals were used in the following experi-
ments: Experiment 1, validation of the viral construct (n 3; see Fig. 1);
Experiment 2, recognition memory tasks (OIP, NOP, NOL) with opto-
genetic stimulation and assessment of neuronal activation (n  14; see
Figs. 2, 3, 4, 5); and Experiment 3, recognition memory task (OIP) with
drug infusions (n 12; see Fig. 6).
Animals were housed under temperature-controlled conditions and
12:12 h reverse light/dark cycle (lights off at 0800 h). Animals were
housed in cages containing environmental enrichment (plastic house,
rope, cardboard tube) in pairs or groups of three after surgery and given
ad libitum access to laboratory chow (Purina) and water. Animal weights
were checked daily after surgery and their growth monitored weekly
against a standard curve for Lister hooded rats. All experiments were
conducted in accordance with the UK Animals (Scientific Procedures)
Act of 1986 and were approved by the local ethical review panel (Univer-
sity of Bristol). Behavioral testing was conducted during the animals’
active phase, between 0800 and 1700 h.
Viral vector construct. Lentiviral vector driven by a CaMKII promo-
ter expressing ChR2 fused to YPF [pLenti-CaMKIIa-hChR2(H134R)-
EYFP-WPRE] from the Karl Deisseroth Laboratory (Boyden et al.,
2005) was prepared by Anja Teschemacher, University of Bristol,
according to standard protocols. For sequence information, see
http://web.stanford.edu/group/dlab/optogenetics/sequence_info.html.
The control group (sham) for the optogenetic–behavioral experi-
ments (Experiment 2) consisted of animals that underwent surgery but
were injected with PBS in place of the viral construct. The within-subject
design of the experiment meant that we could use ChR2-expressing
animals with and without light stimulation as a viral control, which
provides a more specific control for the impact of expression of the
ChR2 on neuronal function than using a control viral vector. Sham
animals also underwent the same light stimulation procedures as the
ChR2-expressing group, thus providing a control for the effects of
light alone.
Surgical procedures. All surgery was performed under aseptic condi-
tions using inhaled isoflurane anesthesia (induction 5%, maintenance
2%, flow rate 2 L/min). Animals were placed in a stereotaxic frame (Da-
vid Kopf Instruments) and fitted with a nose cone for continuous deliv-
ery of anesthetic. Intraepicaine (2%; Dechra) was administered locally
after the skull was exposed for postoperative analgesia. Two small burr
holes were drilled through the skull for injection into the mPFC of the
viral construct (2.5 109 TU/ml, 0.5l per hemisphere, anteroposterior
3.00 mm, lateromedial 0.70 mm, dorsoventral 4.00 mm). Sham
animals received injections of sterile PBS. A stainless steel cannula [outer
diameter (OD) 0.8 mm, inner diameter 0.6 mm, length 13 mm, made in
house] was then implanted down the midline between the two hemi-
spheres to a depth of3.00mm to facilitate access for the optic fiber and
secured in place with bone screws and gentamicin-infused bone cement
(Depuy). An internal obturator was used to prevent cannula blockage.
For Experiment 1, animals received unilateral injection of the viral con-
struct with a sham injection of PBS in the contralateral hemisphere as an
internal control. For Experiment 2, animals received bilateral injections
of either the viral construct or PBS.
For drug infusions (Experiment 3), surgery was performed as above
and as described previously (Benn and Robinson, 2014). Bilateral 22 Ga
stainless steel guide cannula (1.5 mm separation) were implanted into
the mPFC according to the following coordinates relative to bregma;
anteroposterior 3.00 mm, lateromedial 0.75 mm, dorsoventral
2.2mm. After surgery, animals were housed in pairs and given 5–7 d of
recovery time.
Optogenetic stimulation. Animals wereminimally restrained, the obtu-
rator removed, and a conical tipped optic fiber inserted (OD 0.45 mm,
length 14 mm, numerical aperture 0.22; courtesy of G. Danielyan, Gen-
eral Physics Institute Russian Academy of Science, Moscow) into the
mPFC protruding 1.0 mm from the end of the cannula. The optic fiber
was connected to a “Deepstar” pulse-modulated laser (445 nm, 50 mW;
Omicron) via a fine, flexible optical cable (200 m core). The optic fiber
was left in place for 30 s before blue light pulses (two symmetrical beams)
were delivered (5 ms, 50 Hz, 30 s, 1500 pulses total,   473 nm),
allowing for bilateral stimulation of the mPFC. The power output deliv-
ered was confirmed as 8 mW for each stimulation session using a power
meter (Thor Labs). After light stimulation, the optic fiber was removed
and the obturator replaced to maintain patency. Animals were habitu-
ated to fiber insertion and light delivery on two separate occasions before
behavioral testing commenced. The first light stimulation was adminis-
tered 2 weeks after viral injection to allow sufficient time for ChR2 ex-
pression to occur. For behavioral studies, the optical fiber was inserted at
the end of the sample phase, left in place for 30 s, followed by 30 s of light
stimulation (5 ms, 50 Hz, 30 s, 1500 pulses total,   473 nm). The
optical fiber was then removed and the animal held for the remaining
period of the 5 min delay before being returned to the arena for testing.
The control stimulation procedure was identical with the exception that
there was no light stimulation used.
Drug infusions. For Experiment 3, the drug infusion procedure fol-
lowed that of Benn and Robinson (2014). Bilateral 33 Ga stainless steel
cannula that protruded 1.80 mm beyond the end of the guide cannula
were used to facilitate drug infusions into the mPFC. Drugs used were
MMPIP hydrochloride (Tocris Bioscience), CX546 (Sigma-Aldrich),
and CX516 (AdooQ Bioscience). Drugs were dissolved in 0.9% saline
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(CX516), 10% 2-hydroxypropyl--cyclodextrin (CX546), and 25%
2-hydroxypropyl--cyclodextrin (MMPIP), and delivered in a final vol-
ume of 0.5 l per hemisphere (over 1 min, 0.5–1.0 mm3 approximate
spread). Drug doses for CX546 and CX516 were 0.1 and 0.3 g/l based
on EC50 values used in vitro to induce specific effects on EPSPs (Mecha-
war et al., 2000) and the potentiation of PFC neurons in vivo (Johnston et
al., 2003). For MMPIP, 1.0 g/l was used based on previous in vivo
applications within the mPFC (Benn and Robinson, 2014). All animals
received each drug in a fully counterbalanced Latin square design (eight
infusions in total). Animals received two habituation sessions in which
the injector was inserted but no drug infused before behavioral testing.
Behavioral testing. Animals in Experiment 2 (optogenetic–behavioral)
performed all recognition memory tasks (OIP, NOP, and NOL; see Figs.
2, 3, 4). The NOP and NOL tasks were used as control tasks because they
are not thought to involve the mPFC, but rather depend on an intact
perirhinal cortex (NOP) or hippocampus (NOL). Animals in Experi-
ment 3 (see Fig. 6, infusions) performed only the OIP task. Animals were
habituated to the testing arena (50 90 100 cm) for 4 consecutive days
in the absence of objects 7 d after surgery. The NOP, NOL, andOIP tasks
were performed as described previously (Barker et al., 2007). Each task
consisted of a sample phase in which animals were allowed to explore the
objects, followed by a 5 min delay in which the animals were removed
from the arena and either light stimulation or a drug infusion was ad-
ministered. Animals were then placed back into the arena for the test
phase, in which either objects or the spatial locations of objects had been
altered. Time allowed for exploration for each task consisted of; NOP:
40 s total object exploration or 4 min total exploration (sample phase)
followed by 3 min test phase; NOL: 3 min sample phase and 3 min test
phase; and OIP: 5 min sample phase and 3 min test phase. Objects were
cleaned with alcohol between the sample and test phases to remove any
olfactory cues left by the previous animal and also between animals. The
objects used were constructed from the same material; varied in size,
shape, and color; and were only experienced once across the entire study.
Objects and spatial locations were counterbalanced across subjects and
testing days to avoid object and location bias. Animals were allowed to
climb onto and explore around each object in their designated positions.
Exploration was a defined as directing its nose toward the object at a
distance of 2 cm. Climbing on the object or resting against the object
while looking around the arena or grooming was not recorded as explo-
ration time. Exploration time for novel and familiar objects during the
test phase was converted to a discrimination ratio. This was calculated as
the difference in time spent exploring novel objects compared with fa-
miliar object(s)/location(s) divided by the total exploration time of both
objects/locations, which takes into account individual differences in the
total amount of exploration (Ennaceur and Delacour, 1988). A discrim-
ination ratio of zero indicated equal exploration of the novel and familiar
objects. The total amount of exploration across all objects within the
sample and test phases were also analyzed across drug infusion and light
stimulation groups as an indicator of potential confounding factors such
as attentional or locomotive effects on discrimination performance.
For Experiment 2, animals performed each task twice in a within-
subject designwith the optic fiber inserted and light stimulation either on
or off (see Figs. 2, 3, 4, 5). Stimulation conditions (on or off) were coun-
terbalanced between testing days for each animal with the experimenter
blinded to stimulation conditions. Animals received 2 test days per week,
with a minimum of 3 d separating each test day. For the drug infusion
experiments (Experiment 3), animals performed the OIP task only (see
Fig. 6). Doses were administered according to a within-subject fully
counterbalanced Latin square design for each drug in turn (drug order:
CX546, CX516, MMPIP). Animals received 1–2 drug doses per week,
with at least 3 d of separation between infusions and 4 d between the
different drug treatments. The experimenter was blinded to treatment.
Immunohistochemistry. To assess the transduction of glutamatergic
neurons within the mPFC, GFP immunostaining was used to visualize
the expression of the ChR2-YFP fusion protein (see Figs. 1, 5). Neuronal
activation in response to light stimulation was assessed using cFos im-
munoreactivity (see Figs. 1, 5). For cFos staining, animals were killed 90
min after light stimulation and the brains perfused with 4% PFA. Brains
were removed and stored in 30% sucrose before being sectioned in mul-
tiple series (40 m sections). Brain sections were stained using a labeled
streptavidin-biotin (LSAB) or using a two-step fluorescence protocol in
which colocalization was required. The primary antibodies used were;
cFos (1:5000; Calbiochem), GFP (1:5000; Abcam), NeuN (1:1000;
Millipore, clone A60), and GAD67 (1:5000; Millipore, clone 1G10.2).
Secondary antibodies were raised in donkey (anti-rabbit biotin) or goat
(anti-chicken Alexa Fluor 488, anti-rabbit Alexa Fluor 594/647, or anti-
mouse goat anti Alexa Fluor 594) and used at 1:1000.
For Experiment 3, brains were stained with cresyl violet and the loca-
tion of infusion injector tips mapped onto standardized coronal sections
of a rat brain stereotaxic atlas (see Fig. 6B).
Cell quantification. Fluorescent images were acquired throughout the
z-axis (1mintervals, 40magnification) for each channel using a Leica
AOBS SP2 confocal microscope with Ar 488 nm/HeNe 594 nm, and 633
nm laser lines (at theWolfson Bioimaging Facility, University of Bristol).
Manual counts were performed on merged z-projections from each im-
age stack and expressed as the percentage of the total number of GFP cells
counted (minimum 200 per animal). Colocalization was confirmed by
NeuN, GAD67, or cFos nuclear staining surrounded by GFP immuno-
reactivity within the same cell and throughout the z-axis (see Figs. 1, 5).
CFos images were captured from both hemispheres using a Leica
DMIRBE inverted microscope (10magnification) using the same mi-
croscope settings across all images. Counts were performed using the
ImageJ “analyze particles” function across three stereotaxic levels exhib-
iting maximal cFos labeling and expressed as cells per square millimeter.
Cell counts from the prelimbic/infralimbic cortices were performed
blinded to which hemisphere had been injected with the ChR2 construct
(Experiment 1). After completion of behavioral experiments in Experi-
ment 2, the same animals were then used to assess neuronal activation
after light stimulation during the delay phase of the OIP task. These
animals were split into two groups: those that received light stimulation
(“stim ON”) and those that had the optic fiber inserted but received no
light (“stim OFF”). After the delay phase, animals were processed for
cFos staining instead of completing the test phase. The number of cFos
cells per square millimeter was determined within the mPFC (prelimbic
and infralimbic cortices) and connected brain regions thought to be
relevant for associative recognition memory: the perirhinal cortex, thal-
amus, and hippocampus CA1 (Barker et al., 2007; Barker and Warbur-
ton, 2011; Cross et al., 2012). The experimenter was blinded to the
stimulation status of the animal (see Fig. 5).
Statistical analysis. Three animals were excluded from Experiment 2
(optogenetic study) due to cannula blockage, so the final numbers for
analysis were sham n 6 and ChR2 n 7. Two animals were excluded
from Experiment 3 due to hemorrhage based on histology. Animals were
also removed from each drug experiment if exploration levels were20
s during the sample phase and10 s during the test phase or there was an
outlier (1 animal for CX546 and 2 for CX516) consisting of 2 SDs of
the groupmean according to the principles set out inCardinal andAitkin
(2006). Final numbers for Experiment 3 were CX516, n  8; CX546,
n 9, MMPIP n 10.
CFos counts were analyzed using an independent-samples t test
(Experiment 1) and mixed ANOVA with group (sham or ChR2) and
stimulation (on or off) as between-subject factors and region as a within-
subject factor (Experiment 2). Discrimination ratio and test phase
exploration were analyzed using mixed ANOVA with group as the
between-subject factor and stimulation as a within-subject factor for
each recognitionmemory task (Experiment 2). Independent sample t test
was used to compare sample phase exploration between groups (sham vs
ChR2). For the infusion studies, each drug treatment was compared with
its own vehicle control using a RM-ANOVA with treatment as a within-
subject factor. Paired t tests were used to compare the effects of drug
versus vehicle in which only a single dose was tested (MMPIP). Further
analysis was performed using a one-sample t test against a discrimination
value of zero to confirm that animals could discriminate between novel
and familiar objects and locations.
Levene’s test for equality of variance was applied to between-group
analyses and the degrees of freedom adjusted for any violations. Mauch-
ly’s test of sphericity was applied to RM analyses to correct the degrees of
freedom to more conservative values using the Huynh-Feldt epsilon ()
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for any instances of sphericity violation. Alpha level was set at equal to
0.05, with significant main effects being further analyzed by post hoc
comparisons (LSD or Sidak for 3 groups) between groups (stim ON vs
stim OFF, drug dose vs vehicle). All analyses were conducted using SPSS
for Windows (version 21.0) and graphs were plotted using Prism 4.0
(GraphPad software).
Results
Experiment 1: ChR2 construct validation within the mPFC
Immunohistochemistry was used to visualize reporter gene ex-
pression within the adult rodent mPFC and to confirm the cell-
type specificity of the viral construct for glutamatergic pyramidal
neurons.GFP (Fig. 1A) and cFos (Fig. 1B) expression revealed the
selective transduction of neurons (NeuN colocalization 91.2%;
Fig. 1C) with a non-GABAergic phenotype (GAD67 colocaliza-
tion 0.4%; Fig. 1D), indicative of pyramidal neurons within the
mPFC [prelimbic (PL) and infralimbic (IL) cortices]. CFos im-
munohistochemistry was also used to determine the efficacy of
light stimulation parameters to induce neuronal activation. Bi-
lateral light stimulation of the mPFC revealed an increase in
cFos cells within the ChR2-expressing hemisphere compared
with the control hemisphere (Fig. 1B; 180.2 12.9 vs 75.1 11.0
cells/mm2, t test t(2)  18.43, p  0.003). CFos immunoreac-
tivity was also found to colocalize with GFP (ChR2) expression
(Fig. 1C; 48.1 10.6%).
Experiment 2: Effects of optogenetic stimulation on
recognition memory and cFos activation
This experiment tested whether the activation of glutamatergic
neurons during a short delay (5 min) affected discrimination
performance and neuronal activation. Animals were tested in the
OIP, a prefrontal dependent task, and the NOP and NOL tasks,
which do not require the prefrontal cortex for discrimination
Figure 1. Validation of ChR2 expressionwithin the adult rodentmPFC.A, GFP antibody staining showing the expression of the ChR2-YFP fusion proteinwithin themPFC after unilateral injection
of the ChR2 construct (“ChR2” hemisphere). The contralateral hemispherewas injectedwith PBS and acted as an internal control (“control” hemisphere).White line separates the two hemispheres.
The field of view shown (PL/IL) is represented by the striped area on the stereotaxic atlas. B, Antibody staining showing the induction of cFos expression. An increase in the number of cFos cells
in the ChR2-expressing hemisphere versus the control hemisphere was found after bilateral light stimulation of themPFC (180.2 vs 75.1 cells/mm2, t test t(2)18.43, p 0.003). C, Activation
of ChR2-expressing neurons after light stimulationwas confirmedby the colocalization of GFP, NeuN, and cFos (filled arrowheads, 48.1%of GFP-expressing cells).D, ChR2-expressing neurons (filled
arrowheads) did not colocalize with GAD67 (outlined arrowheads), indicating the transfection of a non-GABAergic (pyramidal) phenotype (GFP and GAD67 colocalization 0.4%). Scale bars:
A, B, 500m; C, D, 100m.
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performance (Figs. 2, 3, 4, Table 1). For the OIP task (Fig. 2), an
increase in discrimination was observed in ChR2 animals after
mPFC light stimulation delivered immediately after the sample
phase (stim group F(1.0,11.0) 11.741, p 0.006, stim OFF vs
stim ON t(5)  4.55, p  0.004, n  7). Light stimulation
showed no effect in sham animals (stim OFF vs stim ON, t(5) 
1.29, p 0.253, n 6) in theOIP task.No significantmain effects
of stimulation or group were found (stim F(1,11)  0.01, p 
0.917, group F(1,11)  0.34, p  0.569). All animals, except for
sham animals given light stimulation, showed significant dis-
crimination between objects that had switched locations and
those that had not (sham stim ON t(5)  1.27, p  0.130; sham
stim OFF t(5) 4.25, p 0.004; ChR2 stim OFF t(6) 3.35, p
0.008; ChR2 stim ON t(6)  7.25, p  0.001 vs zero discrimina-
tion). To check that the order of treatment did not affect the
results, we also tested to see whether there was an order effect, but
found no main effect of session (F(1,2)  1.00, p  0.42) or
session*stimulation interaction (F(1,2)  6.26, p  0.129). The
total amount of exploration in the sample phase did not differ
significantly between groups (Table 1; sham vs ChR2 t(11) 1.48,
p  0.167). Total exploration time in the test phase was unaf-
fected by group or stimulation conditions (Table 1; stim F(1,11)
0.05, p  0.832, group F(1,11)  0.13, p  0.731, stim  group
F(1,11) 0.04, p 0.846).
Light stimulation during the delay phase did not affect dis-
crimination performance in the NOP task (Fig. 3; stim F(1,11) 
0.60, p  0.456, group F(1,11)  0.12, p  0.741, stim  group
F(1,11)  0.01, p  0.929). A significant level of discrimination
between novel and familiar objects was shown under all condi-
tions (sham stimOFF t(5) 1.93, p 0.028; sham stimON t(5)
4.65, p 0.003; ChR2 stimOFF t(5) 4.04, p 0.004, ChR2 stim
ON t(5)  3.21, p  0.009 vs zero discrimination). The total
amount of sample exploration did not differ between sham and
ChR2-expressing animals (Table 1; t(11) 0.16, p 0.874), and
neither group nor stimulation affected the overall exploration
time in the test phase (stim F(1,11)  0.67, p  0.802, group
F(1,11) 0.19, p 0.672, stim group F(1,11) 1.61, p 0.231).
Performance in the NOL task was unaffected by mPFC light
stimulation (Fig. 4; stim F(1,11) 0.37, p 0.556, group F(1,11)
0.80, p 0.390, stim group F(1,11) 0.30, p 0.595). Animals
could discriminate significantly between novel and familiar loca-
tions under all conditions (sham stimOFF t(5) 3.54, p 0.009,
sham stimON t(5) 5.01, p 0.002, ChR2 stimOFF t(5) 4.42,
p 0.002, ChR2 stim ON t(5) 5.23, p 0.001 vs zero discrim-
ination). Overall exploration time in the sample and test phases
were not affected by group or stimulation conditions (Table 1;
Table 1. Exploration time during the OIP, NOP, and NOL
Test Group Sample phase (s) Light stimulation Test phase (s)
OIP Sham 116.6 6.6 OFF 58.9 6.4
ON 62.1 11.0
ChR2 127.8 4.2 OFF 63.0 6.8
ON 63.2 4.8
NOP Sham 118.5 10.8 OFF 60.6 11.5
ON 50.7 4.9
ChR2 116.1 9.6 OFF 56.7 5.4
ON 63.2 9.6
NOL Sham 75.3 5.1 OFF 68.2 3.8
ON 46.5 8.0
ChR2 76.0 8.1 OFF 41.7 5.1
ON 51.9 9.3
Shown is the total amount of exploration performed during the 5min (OIP) or 3min (NOL) sample phase or the time
to complete 40 s of exploration in the NOP task. Sample phase exploration did not differ between ChR2-expressing
animals and sham animals. Test phase exploration depicts the total amount of exploration performed during the 3
min test phase for all tasks with and without light stimulation. Test phase exploration was unaffected by group or
light stimulation conditions. Data are shown as mean SEM (sham, n 6; ChR2, n 7).
Figure 2. Light stimulation of glutamatergic neurons and OIP discrimination. Light stimu-
lation was delivered to the mPFC immediately after the sample phase during a 5 min delay
period. Each animal performed the task twice, once with light stimulation (stim ON) and once
without light stimulation (stim OFF), in a fully counterbalanced within-subject design. ChR2-
expressing animals showed an increase in discrimination performance (stim  group
F(1.0, 11.0) 11.741, p 0.006, stim OFF vs stim ON t(5)4.55, p 0.004, n 7). Light
stimulation showed no effect in sham animals (stim OFF vs stim ON, t(5) 1.29, p 0.253,
n6). A significant level of discriminationwas shownbyall groups except shamanimals under
light stimulation conditions (#p 0.05 vs zero). Data shownasmean SEM, **p 0.01 stim
OFF vs stim ON.
Figure 3. Light stimulation of glutamatergic neurons and NOP discrimination. Light stimu-
lation was delivered to the mPFC immediately after the sample phase during a 5 min delay
period. Each animal performed the task twice, once with light stimulation (stim ON) and once
without light stimulation (stimOFF), in a fully counterbalancedwithin-subject design. Discrim-
ination of novel and familiar objects was not affected by mPFC light stimulation in either ChR2
or sham animals. Data are shown as mean SEM for sham (n 6) and ChR2 (n 7).
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sample phase: sham vs virus t(11)  0.07, p  0.947, test
phase: stim F(1,11) 0.55, p 0.473, group F(1,11) 2.72, p
0.127, stim  group F(1,11)  4.28, p  0.063).
To test whether the improvement in OIP performance was
associated with neuronal activation after light stimulation, cFos
immunohistochemistry was used as an indicator of neuronal ac-
tivation and to confirm the efficacy of light stimulation parame-
ters. Brain regions analyzed were based on those considered
relevant to associative recognition memory. Animals that had
completed the behavior tasks were further divided into two
groups: those that would receive light stimulation (“stim ON”)
and those that would not (“stim OFF”). The time point and pa-
rameters of light stimulationwere identical to those administered
during the behavior tests. Animals were allowed to explore ob-
jects in the sample phase of the OIP task, but were processed for
cFos expression after light stimulation instead of continuing on
to the test phase (Fig. 5).
Light stimulation affected cFos expression (Fig. 5A; stim
F(1,9) 8.32, p 0.018, region stim F(5,45) 2.82, p 0.027,
group F(1,9) 8.31, p 0.018), with increases observed in ChR2-
expressing animals for the mPFC (Fig. 5C) andmediodorsal tha-
lamic (MD) regions versus no stimulation (IL, p  0.009; PL,
p  0.009; MD, p  0.007, stim ON vs stim OFF). In ChR2-
expressing animals, neuronal activation was unaffected in the
hippocampus (CA1), paraventricular nucleus (PVA), and
perirhinal cortex (PRh) (CA1, p  0.064; PVA, p  0.059; PRh,
p 0.142). Light stimulation in the absence of ChR2 expression
(sham animals) did not affect the number of cFos cells in any
brain region analyzed (Fig. 5A; CA1, p  0.135; IL, p  0.552;
MD, p 0.603; PL, p 0.281; PRh, p 0.083; PVA; p 0.603,
stimON vs stimOFF). Light stimulation also increased the num-
ber of activated ChR2-expressing neurons, as shown through an
increase in the number of GFP-expressing cells colocalized with
cFos versus no light stimulation (41.5  4.9% vs 18.3  2.0%,
t(5)3.81, p 0.013; Fig. 5B,C).
Experiment 3: AMPAkine infusions and associative
recognition memory
In a separate cohort of animals, drugs that enhance endogenous
glutamatergic activitywere infused into themPFC to test whether
OIP performance could also be improved pharmacologically
(Fig. 6, Table 2). The infusions were given during the delay phase
tomirror the time point of optogenetic stimulation. Two animals
showed the presence of a hemorrhage based on histological ex-
amination and were removed from the analysis; Figure 6B shows
the final injector tip location within the mPFC for the rest of the
cohort.
Infusion ofCX516 into themPFC improvedOIPperformance
(Fig. 6A; F(2,14)  4.95, p  0.024) with an increase in the dis-
crimination ratio at 0.3 g/l (p  0.008), but not 0.1 g/l,
versus vehicle control (p  0.128). At all doses tested, animals
were able to discriminate between objects that had switched lo-
cations and those that had not (0.0 g/l t(7) 3.92, p 0.003,
0.1 g/l t(7) 3.56, p 0.005, 0.3 g/l t(7) 9.17, p 0.001
vs zero discrimination). The total amount of exploration in the
sample or test phases was unaffected by CX516 treatment
(Table 2; sample phase: F(2,14) 2.64, p 0.107, test phase: drug
F(2,14) 0.08, p 0.926).
CX546 treatment showed no effect on OIP performance
(Fig. 6A; F(2,16)  0.73, p  0.499). Animals showed a signifi-
cant level of discrimination versus zero (0.0 g/l t(8) 2.42,
p  0.021, 0.1 g/l t(8)  1.83, p  0.053) except at the
highest dose of 0.3 g/l (t(8)  1.16, p  0.140). Drug treat-
ment did not affect the overall exploration time in the sample
phase or test phase (Table 2; sample phase: F(1.3,10.3)  1.28,
p  0.298,   0.65, test phase: F(2,16)  0.77, p  0.479).
Discrimination performance was unaffected byMMPIP infu-
sions (Fig. 6A; t(9)  0.38, p  0.710). All animals could dis-
criminate between objects that had switched locations and those
that had not after MMPIP treatment (0.0 g/l t(9) 2.99, p
0.008, 1.0 g/l t(9)  4.52, p  0.001). The total amount of
exploration in the sample and test phases was no different to
vehicle treatment (Table 2; sample phase: t(9)1.26, p 0.240,
test phase: t(9)1.36, p 0.206).
Discussion
These data show that light-induced activation of mPFC glutama-
tergic pyramidal neurons during the delay phase of the OIP task
improves associative recognition memory. The lack of effects of
the same stimulation onNOP or NOL performance suggests that
this effect is specific to associative rather than single-item recog-
nition memory. Furthermore, light stimulation induced neuro-
nal activation, not only in the immediate vicinity of the optic fiber
(PL and IL cortices), but also in subregions (MD thalamus)
known to be connected reciprocally to the PL cortex and impor-
tant for discrimination performance in the OIP task (Cross et al.,
2012). The dissociation between the effects of the AMPAkine
CX516 versus CX546 suggests that modulating the amplitude of
glutamatergic EPSPs, but not the duration, is important. The lack
of effect of MMPIP shows that enhanced glutamate release alone
does not replicate the effects of optogenetic stimulation. These
results confirm a specific role formPFC glutamatergic neurons in
recognition memory tasks that require the integration of both
spatial and object recognition information. These studies also
provide evidence that selective activation of glutamatergic neu-
rons after acquisition can improve short-term OIP memory.
Figure 4. Light stimulation of glutamatergic neurons and NOL discrimination. Light stimu-
lation was delivered to the mPFC immediately after the sample phase during a 5 min delay
period. Each animal performed the task twice, once with light stimulation (stim ON) and once
without light stimulation (stimOFF), in a fully counterbalancedwithin-subject design. Discrim-
ination of novel and familiar locationswas not affected bymPFC light stimulation in either ChR2
or sham animals. Data are shown as mean SEM for sham (n 6) and ChR2 (n 7).
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Light-induced activation of the mPFC and
glutamatergic neurons
Using cFos expression to identify neuronal activation, we showed
a large difference in the number of cells expressing cFos in the
ChR2-expressing hemisphere. The very low level of expression
observed in the sham hemisphere confirms that light stimulation
alone did not activate neurons in the nearby region. These find-
ings verified the specificity of transgene expression and activation
Figure 5. Neuronal activation after light stimulation during the OIP task. A, Light stimulation was delivered to animals that had performed the sample phase of the OIP task. Sham and ChR2
animalswere further divided into stimONor stimOFF groups in a between-subject design. Neuronal activationwas increased in ChR2-expressing animals after light stimulation in the PL, IL, andMD
regions (IL, p 0.009; PL, p 0.009; MD, p 0.007; stim ON vs stim OFF).B, C, GFP and cFos antibody stainingwithin the PL of ChR2-expressing animals. Light stimulation increased the number
of activated ChR2-expressing neurons (C, stim ON 41.5% vs B, stim OFF 18.3%, t(5)3.81, p 0.013), asterisk depicts high-magnification view of GFP and cFos colocalization. Scale bars: C,D,
100m; C, high-magnification, 20m. Data presented as mean SEM for sham stim OFF (n 3), sham stim ON (n 3), ChR2 stim OFF (n 3), and ChR2 stim ON (n 4). *p 0.05, **p
0.01, ChR2 stim OFF versus stim ON.
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using defined light stimulation parameters, consistent with pre-
vious reports (Zhang et al., 2006; Covington et al., 2010).We also
showed an increase in activation of virally transduced neurons in
both hemispheres after light stimulation during the delay phase
at the end of the behavioral experiments. Using cFos as ameasure
of neuronal activation versus electrophysiological methods has
limitations regarding interpreting the temporal dynamics of
evoked neural activity. It is likely that neural activation persisted
throughout the stimulation period due to
the temporal correlation of evoked spike
activity to single light pulses reported pre-
viously (Cardin et al., 2010). Increases in
mPFC cFos activation can occur up to 30
min after light delivery (Covington et al.,
2010), so prolonged effects on neuronal
activation in the absence of light delivery
cannot be ruled out here. Despite the po-
tential limitations of cFos as a marker of
neuronal activity, these data do confirm
the specificity of expression and lack of
nonspecific effects of light stimulation
alone within the mPFC. The extent of
neuronal activation was also reflected
in the area of cFos activation, suggesting
that light stimulation affected neurons
throughout the mPFC and within con-
nected regions such as the thalamus.
Contribution of glutamatergic neurons
to associative recognition memory
Blockade of both NMDA-R and AMPA-R
cause impairments in OIP performance
through disrupting the acquisition, but
not the retrieval, of information (Barker
and Warburton, 2008). This implies that
fast excitatory transmission is required at
only certain points during the task. What
these drug studies cannot show is how the
different cell types contribute to memory.
We show how selective activation of
glutamatergic neurons during the delay
phase improved OIP performance. Neu-
rons are known to alter their firing
characteristics during the delay phase of
short-term memory tasks during the en-
coding of information (Goldman-Rakic
et al., 2000; Chang et al., 2002). Our data
suggest that activating glutamatergic neu-
rons through optogenetic stimulation
during this period improves associative
recognition memory. CX516 also improved OIP discrimination,
possibly through similar mechanisms, due to improvements be-
ing synonymous with increased neuronal activity during the de-
lay phase (Hampson et al., 1998). Previous studies have shown
evoked increases in firing in single glutamatergic neurons in re-
sponse to optogenetic stimulation (Bernstein and Boyden, 2011;
Ji and Neugebauer, 2012). It might be expected that optogenetic
stimulation would induce disrupted firing patterns by inducing
action potentials in ChR2-expressing neurons (Ji and Neuge-
bauer, 2012). The predicted effects of this outcome would be a
disruption to memory function. Based on our findings, we hy-
pothesis that our optogenetic effects are more akin to changes in
firing thresholds that potentiate network activity, as shown by
AMPAkines (Hampson et al., 2009), resulting in increased cFos
activation within behaviorally relevant brain areas and improved
OIP discrimination. No effects on performance were observed in
the NOP andNOL tasks, which served as important control tasks
due to the lack of involvement of the mPFC for single-item dis-
crimination of objects or locations (Barker et al., 2007). In sup-
port of our hypothesis, OIP performance was also enhanced
using the AMPAkine CX516, but not CX546 or MMPIP. CX516
Figure 6. Effect of CX546, CX516, andMMPIP on OIP discrimination.A, Drug infusionswere delivered to themPFC immediately
after the sample phase during a 5 min delay period. CX516 improved OIP performance (F(2,14) 4.95, p 0.024, 0.3 g/l
p 0.008); CX546 and MMPIP showed no effect on discrimination. B, Final injector tip placement of infusion cannula within the
mPFC. Injector placements for two animals thatwere removeddue to hemorrhage are not shown. Data are shownasmean SEM
for CX546 (n9), CX516 (n8), andMMPIP (n10). **p0.01 versus vehicle. A significant level of discriminationwas shown
by all groups except for animals treated with 0.3g/l CX546 (#p 0.05 vs zero).
Table 2. Exploration time for infusion animals performing the OIP
Drug Dose (g/l) Sample phase (s) Test phase (s)
CX546 0.0 103.4 4.9 35.1 3.8
0.1 113.6 7.5 43.7 5.9
0.3 112.2 7.6 40.5 4.6
CX516 0.0 114.4 9.0 47.8 3.2
0.1 98.7 4.1 51.2 5.7
0.3 120.6 6.9 48.9 8.8
MMPIP 0.0 105.3 6.4 38.4 3.0
1.0 116.4 11.5 48.7 5.6
The total amount of exploration performed during the sample phase (5 min) and test phase (3 min) of the OIP was
unaffected by drug treatment. Data are shown as mean SEM (CX546, n 9; CX516, n 8; MMPIP, n 10).
Benn et al. • Stimulation of Prefrontal Glutamatergic Neurons J. Neurosci., May 4, 2016 • 36(18):4930–4939 • 4937
and CX546 have both shown efficacy in reversing PCP-induced
deficits in novel object discrimination (Damgaard et al., 2010).
We extend these findings to include a dissociable effect on asso-
ciative recognition memory involving the mPFC in normal ani-
mals. Our infusion data suggest that the way in which
glutamatergic transmission is modulated is crucial to its efficacy
in this cognitive task.
CX516 andCX546 differ in their effects on excitatory postsyn-
aptic currents. CX546 is more potent in reducing receptor desen-
sitization and increasing EPSP duration compared with the
amplitude-enhancing effects of CX516 and the promotion of
LTP induction (Audet et al., 1988;Gabbott et al., 1997;Mechawar
et al., 2000; Arai et al., 2002). Correlating behavioral effects to
differences in AMPAkine receptor kinetics has been investigated
previously (Davis et al., 1997). Our results indicate that enhanc-
ing the amplitude of the EPSP response through CX516 treat-
ment enhances the online maintenance of memory encoding in
normal animals and also appears to mimic the effects observed
with optogenetic stimulation. This suggests the efficacy of the
latter may arise from an excitatory effect on a similar neuronal
population in vivo. We believe that these effects are specific to
recognition memory processes and not due to motor or atten-
tional effects because the overall exploration time across the sam-
ple and test phases was unaffected by light stimulation or drug
administration. In addition, NOP and NOL performance was
also unaffected by light stimulation, which further substantiates
the specificity of our findings.
Regional activation after light stimulation of mPFC neurons
The pattern of cFos expression showed that light stimulation
during the delay phase in ChR2 animals was increased in the PL,
IL, and MD thalamus, but not in the hippocampus or perirhinal
cortex. Our results suggest that light stimulation of glutamatergic
neurons within the mPFC enhances OIP recognition memory,
which we can link to enhanced activation within the corticotha-
lamic circuit. This was confirmed by an increase in cFos activa-
tion within the MD thalamus, an area with strong reciprocal
excitatory connections to the mPFC (Pirot et al., 1994) and im-
portant for OIP performance (Cross et al., 2012). Our cFos data
also shows that, after completion of the behavioral tests, gluta-
matergic neurons transduced with the ChR2 construct were still
functionally responsive to light stimulation.
Stimulation in the absence of ChR2 expression did not
result in any significant increase in cFos expression in any
region analyzed. Sham animals were able to discriminate in
the NOP and NOL tasks under light stimulation conditions,
but were unable to discriminate in the OIP task. Overall per-
formance levels in the control conditions were lower than
previously reported by Barker et al. (2007, 2008); however,
they were consistent across both the optogenetic and drug-
infusion studies. We tested for an order effect for light stimu-
lation, but did not find any evidence to suggest that this was a
factor in the results observed. It is possible that light alone in
the mPFC had a small detrimental effect on OIP performance
despite laser power being consistent across all stimulation ses-
sions. Although increases in brain temperature have been as-
sociated with blue light stimulation (Christie et al., 2012) and
cortical cFos expression (du Plessis et al., 2006), light stimu-
lation in sham animals did not affect cFos activation in the
regions of interest. It is unclear as to the mechanism respon-
sible for performance deficits in these animals; however, the
lack of effects in the two control tasks and significant differ-
ence between stimulation on versus off conditions for the
ChR2-expressing animals does suggest a specific effect.
Our data indicate specific changes in discrimination after a
short delay period, indicative of effects on short-term recognition
memory. Other effects such as attentional changes or motiva-
tional effects may also have an effect, although control measures
such as total exploration time and the lack of effects on non-PFC-
dependent behaviors would not support this. Effects on long-
termmemorymay also be observed if the animals were tested at a
later time point, but this was beyond the scope of this particular
piece of work. Without additional studies, we cannot fully ex-
clude the possibility of effects due to factors other than short-
term recognition memory.
In summary, targeting treatments to increase specifically the
amplitude of the glutamatergic EPSP may provide the most ef-
fectivemechanism to enhance PFC-mediated cognitive function.
This work also highlights the benefits of cell-type-targeted opto-
genetic manipulations to investigate the behavioral functions
and mechanisms that underlie the activity of specific neuronal
subpopulations.
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